Complete remission in a patient with treatment refractory bullous pemphigoid after a single dose of omalizumab

Abstract

Bullous pemphigoid (BP) is an autoimmune disorder known to be mediated by immunoglobulin G (IgG) autoantibodies. The role of immunoglobulin E (IgE) antibodies is being investigated as their presence has been described in severe cases. Herein, we report a patient of BP who was refractory to most conventional agents and developed hypotension after rituximab but achieved lasting remission after a single dose of the anti-IgE monoclonal antibody omalizumab.

Keywords

• bullous pemphigoid
• immunoglobulin e
• omalizumab
• refractory